Provided by Integrity Continuing Education, Inc.
Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Until recently the only treatment choices for patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), a chronic inflammatory condition of the sinonasal cavities, included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery. But as the pathophysiologic mechanisms of asthma began to be unraveled, a common endotype of T-helper cell type 2 (TH2) inflammation began to emerge, showing shared molecular mechanisms between severe asthma and uncontrolled CRS. Researchers realized that the monoclonal antibody treatments developed to treat severe asthma could also be an effective treatment option for CRSwNP. These biologic agents target common TH2 inflammatory drivers that are endotypic of both upper and lower respiratory atopic disorders; specifically, interleukin (IL) cytokines IL-4, IL-5, and IL-13, and circulating or local immunoglobulin E (IgE).
Of the upper inflammatory disorders, perhaps the most recalcitrant and refractory is CRSwNP. Nasal polyposis is typically present in patients with the highest levels of disease severity, and endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery.
Novel biologics that were successful in controlling some forms of severe asthma were put into clinical trials to evaluate their impact on CRSwNP. Availability of biologics for CRSwNP gives clinicians treatment options beyond steroids and surgery for their CRSwNP patients who are struggling to breathe freely. However, it also confronts them with new and different decisions. This program has been designed to address questions surrounding the use of biologics when treating patients with CRSwNP.
Joseph K. Han, MD
Department of Otolaryngology
Eastern Virginia Medical School
This educational activity has been designed to meet the needs of allergists, immunologists, and specialty nurse practitioners (NPs)/physician assistants (PAs).
Upon completion of this educational activity, participants should be able to:
There is no registration fee for participating in this activity. To register, click the registration buttons on this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.
Physician Continuing Education
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Joseph K. Han, MD
Consultant: AstraZeneca, Genetech Novartis, GlaxoSmithKline, Regeneron, Sanofi Genzyme
The Integrity Continuing Education, Inc planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
On the day of the program, you may access the event by going to any of the following links:
Hybrid Live: www.integrityce.com/CRSwNP6
There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME credit(s)™. To do so, you must participate in the virtual live stream activity and complete the posttest and evaluation following the event. A statement of credit will be issued only upon submission of a completed activity evaluation form.